Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate the Safety and Efficacy of IQP-CL-101 in the Symptomatic Improvement of Irritable Bowel Syndrome (IBS)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Nutrient formulae (Primary)
- Indications Irritable bowel syndrome
- Focus Biomarker; Therapeutic Use
- 26 Mar 2015 Biomarkers information updated
- 29 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 01 Feb 2013 New trial record